Novartis Can't Claw Back Atty Email In Terbutaline Drug Suit
An email by a Novartis attorney inadvertently presented in litigation over the drug terbutaline should be unsealed, as the pharmaceutical company subsequently failed to do enough to protect and preserve its...To view the full article, register now.
Already a subscriber? Click here to view full article